These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37283508)

  • 1. Surgery for locally advanced gastric cancer in the era of neoadjuvant therapies: something new?
    Rosa F; Laterza V; Schena CA; Tondolo V; Strippoli A; Covino M; Pacini G; Quero G; Fiorillo C; DE Sio D; Tortora G; Alfieri S
    Minerva Surg; 2023 Oct; 78(5):481-489. PubMed ID: 37283508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative chemotherapy versus adjuvant chemotherapy treatment for resectable locally advanced gastric cancer: a retrospective cohort study.
    Su P; Jiang L; Zhang Y; Yu T; Huang H; Chen M; Cao C; Kang W; Liu Y; Yu J
    Eur J Med Res; 2023 Oct; 28(1):409. PubMed ID: 37814327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between upfront surgery and neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A systematic review.
    Fiflis S; Papakonstantinou M; Giakoustidis A; Christodoulidis G; Louri E; Papadopoulos VN; Giakoustidis D
    World J Gastrointest Surg; 2023 Aug; 15(8):1808-1818. PubMed ID: 37701690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term survival results of patients with locally advanced gastric cancer and pathological complete response after neoadjuvant chemotherapy and resection.
    Wang T; Wang N; Zhou H; Zhou A; Jin J; Chen Y; Zhao D
    Transl Cancer Res; 2020 Feb; 9(2):529-535. PubMed ID: 35117397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Neoadjuvant Chemotherapy Toxicity and Postoperative Complications on Short-term and Long-term Outcomes After Curative Resection of Gastric Cancer.
    Wu C; Wang N; Zhou H; Wang T; Mao Q; Zhang X; Zhao D
    J Gastrointest Surg; 2020 Jun; 24(6):1278-1289. PubMed ID: 31140064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
    Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Neoadjuvant Therapies for Patients with Locally Advanced Gastric Cancer: A Propensity Score Matching Study.
    Wang T; Chen Y; Zhao L; Zhou H; Wu C; Zhang X; Zhou A; Jin J; Zhao D
    J Cancer; 2021; 12(2):379-386. PubMed ID: 33391434
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy.
    Persiani R; D'Ugo D; Rausei S; Sermoneta D; Barone C; Pozzo C; Ricci R; La Torre G; Picciocchi A
    J Surg Oncol; 2005 Mar; 89(4):227-36; discussion 237-8. PubMed ID: 15726615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open vs. laparoscopic surgery for locally advanced gastric cancer after neoadjuvant therapy: Short-term and long-term survival outcomes.
    Wang N; Zhou A; Jin J; Huang H; Zhang Y; Chen Y; Zhao D
    Oncol Lett; 2020 Jul; 20(1):861-867. PubMed ID: 32566013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis.
    Zhang X; Huang H; Wei Z; Zhu Z; Yang D; Fu H; Xu J; Hu Z; Zhang Y; You Q; Huang X; Yan R; Wang W; Cai Q
    Cancer Manag Res; 2020; 12():6641-6653. PubMed ID: 32801898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival Benefit of Perioperative Chemotherapy in Patients with Locally Advanced Gastric Cancer: a Propensity Score Matched Analysis.
    Eom BW; Kim S; Kim JY; Yoon HM; Kim MJ; Nam BH; Kim YW; Park YI; Park SR; Ryu KW
    J Gastric Cancer; 2018 Mar; 18(1):69-81. PubMed ID: 29629222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the predictive value of pathological response at primary tumor and lymph node status after neoadjuvant chemotherapy in locally advanced gastric cancer.
    Su P; Zhang Y; Yu T; Jiang L; Kang W; Liu Y; Yu J
    Clin Transl Oncol; 2023 Aug; 25(8):2462-2471. PubMed ID: 37093455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttherapy topographical nodal status, ypN-site, predicts survival of patients who received neoadjuvant chemotherapy followed by curative surgical resection for non-type 4 locally advanced gastric cancer: supplementary analysis of JCOG1004-A.
    Fujitani K; Nakamura K; Mizusawa J; Kuwata T; Shimoda T; Katayama H; Kushima R; Taniguchi H; Yoshikawa T; Boku N; Terashima M; Fukuda H; Sano T; Sasako M;
    Gastric Cancer; 2021 Jan; 24(1):197-204. PubMed ID: 32572792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative study on prognosis of neoadjuvant chemotherapy followed by hepatic surgery versus upfront surgery in patients with synchronous colorectal liver metastasis].
    Wang LJ; Wang HW; Jin KM; Liu W; Bao Q; Wang K; Xing BC
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):248-255. PubMed ID: 34645169
    [No Abstract]   [Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
    Fossaert V; Mimmo A; Rhaiem R; Rached LJ; Brasseur M; Brugel M; Pegoraro F; Sanchez S; Bouché O; Kianmanesh R; Piardi T
    Front Oncol; 2022; 12():980659. PubMed ID: 36387257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant therapy with immune checkpoint inhibitors in combination with chemotherapy vs . chemotherapy alone in HER2(-) locally advanced gastric cancer: A propensity score-matched cohort study.
    Xu G; Liu T; Shen J; Guan Q
    Chin Med J (Engl); 2024 Feb; ():. PubMed ID: 38420853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.
    Wang T; Li C; Li X; Zhai J; Wang S; Shen L
    Eur J Med Res; 2022 Nov; 27(1):239. PubMed ID: 36352476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.